secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001437749-23-010655
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Biotherapeutics receives FDA Breakthrough Therapy Designation for influenza therapeutic SAB-176
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation to SAB-176 for post-exposure prophylaxis of Type A/B influenza in high-risk patients.
- SAB-176 previously received Fast Track designation on April 13, 2023; both designations rarely obtained together.
- Breakthrough Therapy provides intensive FDA guidance, eligibility for priority review, and expedited development.
- SAB-176 is a fully human multi-epitope binding polyclonal antibody, reducing risk of viral escape mutations.
- Phase 2b dose-ranging efficacy and safety trial planned following FDA regulatory alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923010655/0001437749-23-010655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000143774923010655/sabs20230418_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-010655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer